Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights to drug candidate dersimelagon from Tanabe Pharma for up to $435 million in up-front and near-term milestone payments.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.